eQcell Inc Announces the Appointment of Members of the Board of Directors
Guelph, ON, Canada April 12, 2021 – eQcell Inc. Canada’s premier clinical-stage regenerative medicine company addressing conditions and diseases affecting sporting and domestic animals globally, announces the appointment to its Board of Directors of Mr. David Allan.
Mr. Allan, a former investment banker and Governor of the Toronto Stock Exchange, was the founder, Chairman and CEO of the US-listed YM BioSciences; Executive Chairman of Stem Cell Therapeutics, now Trillium Therapeutics, and Founding Chairman of Formation Biologics. He is a member of the Advisory Board of Haygain Ltd, the internationally-recognized company in equine health and well-being, and of Inteligex Inc., developing neural stem cells for the treatment of spinal cord injury. He is the recipient of the Julia Levy Award for commercialization of bio-medical innovation; the Life Sciences Ontario Leadership Award; and the BIOTEC Canada Gold Leaf Award for Industry Leadership. He has been a member of the Awards Selection Committee of Canada's Network of Centers of Excellence and the Multidisciplinary Assessment Committee of the Canada Foundation for Innovation.
“The eQcell approach to the regenerative solution for human and veterinary conditions that have no, or ineffective, treatments is so profoundly impressive,” said David Allan, “that participating in the transformational financing round was compelling.” “eQcell leads the field in the recognition that the equine model has direct relevance to human medicine, profoundly reducing time-to-market for both veterinary and human stem cell therapeutics.
About eQcell Inc.
eQcell was founded by Dr. Thomas Koch, Associate Professor at the University of Guelph, Canada, ranked fifth in the world in veterinary medicine. The company’s work in stem cells has been supported by grants and expenditures approximating $6 million over a 15-year period. The company is considered Canada’s premier clinical-stage regenerative medicine company addressing conditions and diseases affecting sporting and companion animals globally for which current treatments are ineffective, not fully effective, or palliative. eQcell has developed allogeneic equine cord blood stem cells as well as canine adipose-derived mesenchymal stromal cells to provide novel therapeutic options. Dr. Koch is currently assessing laboratory-generated cartilage from neonatal allogeneic mesenchymal stromal cells (MSC) in cartilage defects in horses under a grant from the Canadian Institute for Health Research (CIHR) that recognizes the prospect for the equine model’s application to humans. The trial is considered to have high translational potential in that success of the project would lead to new technology development and treatment for cartilage defects in equine and humans.
For further information:
Dr. Thomas Koch (email@example.com)
University of Guelph
50 Stone Road East
Guelph, Ontario N1G 2W1